{"id":"once-daily-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport from the bloodstream into muscle, fat, and liver cells. Once-daily formulations use extended-release technology to provide sustained insulin levels throughout the day, reducing the frequency of injections needed for glycemic control in diabetes management.","oneSentence":"Once-daily insulin replaces or supplements the body's natural insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:20.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT07460336","phase":"NA","title":"Effects of Cofrogliptin on Beta-Cell Function in LADA Patients","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-15","conditions":"Latent Autoimmune Diabetes in Adults (LADA)","enrollment":84},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT07120828","phase":"PHASE4","title":"The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity","status":"COMPLETED","sponsor":"Erbil Polytechnic University","startDate":"2025-07-15","conditions":"Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":260},{"nctId":"NCT07472179","phase":"NA","title":"Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-08-12","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT07472920","phase":"NA","title":"Empagliflozin Adjunctive Therapy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03-09","conditions":"Bipolar Disorder, Bipolar Depression, Insulin Resistance","enrollment":20},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT07463417","phase":"NA","title":"Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women","status":"COMPLETED","sponsor":"Sarah Wragge Wellness","startDate":"2024-04-01","conditions":"Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring","enrollment":85},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT02088658","phase":"NA","title":"Technology Intensified Diabetes Education Study in African Americans","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2013-05","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":200},{"nctId":"NCT07453680","phase":"NA","title":"Comparative Effect of Myo-inositol With That of D-chiro-inositol on Insulin Resistance in Infertile Women With Polycystic Ovary Syndrome (PCOS).","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2023-06-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":80},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT06111508","phase":"NA","title":"The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2023-11-29","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07348809","phase":"NA","title":"The Effects Of Virtual Reality and Stress Ball Application on Pain, Anxiety Levels and Injection Satisfaction in During Insulin Injection in Geriatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tarsus University","startDate":"2024-11-01","conditions":"Diabete Type 2, Virtual Reality, Stress Ball","enrollment":90},{"nctId":"NCT05279768","phase":"PHASE1, PHASE2","title":"Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.","status":"COMPLETED","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2022-09-01","conditions":"Polycystic Ovary Syndrome","enrollment":44},{"nctId":"NCT07371169","phase":"NA","title":"Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin Resistance","status":"COMPLETED","sponsor":"Uruk University","startDate":"2025-01-01","conditions":"Insulin Resistance, Acanthosis Nigricans","enrollment":90},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT06330194","phase":"NA","title":"Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-04-18","conditions":"Dialysis, Chronic Kidney Disease, Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT06227221","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-02","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT07405944","phase":"PHASE4","title":"Vericiguat and Reverse Remodeling Indices in Heart Failure","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-11-01","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure","enrollment":60},{"nctId":"NCT07224334","phase":"PHASE1","title":"Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.","status":"RECRUITING","sponsor":"David D'Alessio, M.D.","startDate":"2025-12-30","conditions":"Diabetes (DM)","enrollment":30},{"nctId":"NCT04666636","phase":"PHASE2","title":"Mechanisms for Activation of Beige Adipose Tissue in Humans","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2020-12-07","conditions":"PreDiabetes","enrollment":65},{"nctId":"NCT07373392","phase":"NA","title":"Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University","startDate":"2026-01-25","conditions":"Diabete Type 1, Diabete Type 2, Prediabetes","enrollment":210},{"nctId":"NCT07220694","phase":"NA","title":"Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance","status":"RECRUITING","sponsor":"SF Research Institute, Inc.","startDate":"2026-01-29","conditions":"Insulin Resistance, Mild Cognitive Impairment, Cognitive Decline","enrollment":140},{"nctId":"NCT06320951","phase":"PHASE2","title":"VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-12-01","conditions":"Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease","enrollment":200},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT05803421","phase":"PHASE3","title":"A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-03","conditions":"Type 2 Diabetes, Obesity, Overweight or Obesity","enrollment":2749},{"nctId":"NCT06915428","phase":"NA","title":"Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02-01","conditions":"Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence","enrollment":1228},{"nctId":"NCT07334951","phase":"NA","title":"Effect of Tvns in Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2026-01-11","conditions":"Obesity and Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT07112339","phase":"PHASE4","title":"A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-15","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT07307677","phase":"NA","title":"Melatonin & Metformin on Clinical & Biochemical Parameters in Insulin Resistant PCOS Compared to Metformin","status":"RECRUITING","sponsor":"Mst.Sumyara Khatun","startDate":"2025-03-11","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT06229795","phase":"PHASE3","title":"Effect of Green Tea on Obese Pediatrics With Prediabetes","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-11-12","conditions":"PreDiabetes","enrollment":90},{"nctId":"NCT00628212","phase":"PHASE2","title":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT00998881","phase":"PHASE3","title":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT01072331","phase":"PHASE3","title":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT07247734","phase":"PHASE2","title":"The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation","status":"RECRUITING","sponsor":"Asger Lund, MD","startDate":"2025-12-01","conditions":"Type 1 Diabetes, Chronic Inflammation, Insulin Sensitivity","enrollment":26},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT07271212","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT05352815","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-06-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1291},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT04771754","phase":"PHASE1","title":"The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-03-20","conditions":"HIV-1-infection on Healthy Volunteers","enrollment":16},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT06767735","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-17","conditions":"Diabetes","enrollment":580},{"nctId":"NCT06767761","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-18","conditions":"Diabetes","enrollment":580},{"nctId":"NCT05514535","phase":"PHASE3","title":"A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-29","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":568},{"nctId":"NCT03919929","phase":"PHASE2, PHASE3","title":"Treating PCOS With Semaglutide vs Active Lifestyle Intervention","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-05-03","conditions":"PCOS, Adolescent Obesity, NAFLD","enrollment":60},{"nctId":"NCT06767748","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-15","conditions":"Diabetes","enrollment":620},{"nctId":"NCT07242664","phase":"PHASE1","title":"Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-10-13","conditions":"Type 1 Diabetes Mellitis","enrollment":12},{"nctId":"NCT07045298","phase":"NA","title":"CGM Use in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Heart Failure, Diabetes Mellitus","enrollment":140},{"nctId":"NCT07224893","phase":"PHASE4","title":"Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","status":"NOT_YET_RECRUITING","sponsor":"Eastern Virginia Medical School","startDate":"2025-12-01","conditions":"Pregestational Diabetes, Pregnancy","enrollment":200},{"nctId":"NCT04029480","phase":"PHASE3","title":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT05090358","phase":"PHASE2","title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-08","conditions":"Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT06109311","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-10","conditions":"Type 2 Diabetes","enrollment":546},{"nctId":"NCT06420518","phase":"","title":"Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.","status":"COMPLETED","sponsor":"McGill University","startDate":"2024-04-30","conditions":"type1diabetes","enrollment":16},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05002933","phase":"PHASE4","title":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-05-20","conditions":"Type 2 Diabetes Mellitus","enrollment":570},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT06282458","phase":"PHASE2","title":"Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt","status":"COMPLETED","sponsor":"Veru Inc.","startDate":"2024-04-29","conditions":"Muscle Loss, Obesity","enrollment":168},{"nctId":"NCT07177781","phase":"NA","title":"Effects of Wild Blueberry Consumption on Brain Function in Elderly","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-12-05","conditions":"Brain Insulin-sensitivity, Brain Vascular Function, Cerebral Blood Flow","enrollment":36},{"nctId":"NCT02256865","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2014-10","conditions":"Insulin Resistance","enrollment":40},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT06340854","phase":"PHASE3","title":"A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-19","conditions":"Diabetes, Type 2","enrollment":429},{"nctId":"NCT06269107","phase":"PHASE3","title":"A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Type 2 Diabetes","enrollment":485},{"nctId":"NCT07146347","phase":"PHASE1","title":"Comparison Study of Insulin GZR4 With Insulin Degludec","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-08-15","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT06985121","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence","status":"COMPLETED","sponsor":"Hungkuang University","startDate":"2025-04-08","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT05662332","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-01-14","conditions":"Type 2 Diabetes, T2D","enrollment":795},{"nctId":"NCT06731075","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.","status":"NOT_YET_RECRUITING","sponsor":"Oramed, Ltd.","startDate":"2025-12-15","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT06605872","phase":"","title":"DigiDiab Pilot: Impact Study Hospital","status":"RECRUITING","sponsor":"Medical University of Graz","startDate":"2025-04-01","conditions":"Type 2 Diabetes","enrollment":500},{"nctId":"NCT07097974","phase":"NA","title":"Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change","status":"NOT_YET_RECRUITING","sponsor":"TCI Co., Ltd.","startDate":"2025-08-31","conditions":"Obesity","enrollment":40},{"nctId":"NCT06717191","phase":"PHASE4","title":"Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-09","conditions":"Type 1 Diabetes","enrollment":296},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06818851","phase":"PHASE4","title":"The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy","status":"RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-07-14","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT07067515","phase":"PHASE1, PHASE2","title":"Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suez Canal University","startDate":"2024-01-03","conditions":"Hyperpigmentation, Gingival Hyperpigmentaion","enrollment":30},{"nctId":"NCT06836128","phase":"PHASE3","title":"The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-03-01","conditions":"Polycystic Ovary Syndrome","enrollment":102},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT02500147","phase":"PHASE4","title":"Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2011-09-08","conditions":"Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome","enrollment":3},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT05124132","phase":"NA","title":"Resilience and Brain Health of Older Adults (MEDEX-2)","status":"ENROLLING_BY_INVITATION","sponsor":"Washington University School of Medicine","startDate":"2019-04-16","conditions":"Age-related Cognitive Decline","enrollment":468},{"nctId":"NCT05275400","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-03-08","conditions":"Type 2 Diabetes","enrollment":986},{"nctId":"NCT05780151","phase":"PHASE4","title":"Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)","status":"COMPLETED","sponsor":"Mira Zuidgeest","startDate":"2023-07-10","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT06288412","phase":"PHASE1","title":"A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-26","conditions":"Diabetes Mellitus, Type 2","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":270,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Once-daily Insulin","genericName":"Once-daily Insulin","companyName":"Hospital Universitario Dr. Jose E. Gonzalez","companyId":"hospital-universitario-dr-jose-e-gonzalez","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Once-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}